Aprea Therapeutics
APRE
28 hedge funds and large institutions have $1.9M invested in Aprea Therapeutics in 2026 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 2 closing their positions.
300% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 2
27% more funds holding
Funds holding: 22 → 28 (+6)
11% more capital invested
Capital invested by funds: $1.71M → $1.9M (+$190K)
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
0.45% less ownership
Funds ownership: 19.6% → 19.15% (-0.45%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$67.3K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$48.9K |
| 3 |
DP
Diadema Partners
Morristown,
New Jersey
|
+$37.5K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$18.3K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$11.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SRL
Scientech Research LLC
Jersey City,
New Jersey
|
-$46K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$36.9K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$10.3K |
| 4 |
LPL Financial
San Diego,
California
|
-$4.17K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$1.79K |
APRE Hedge Fund Activity: Q2 2026 in Review
28 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Aprea Therapeutics (APRE) for Q2 2026, worth a combined $1.9M — up 11% from $1.71M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new APRE positions and 2 closed out — a net gain of 6 holders — while 5 added to existing stakes and 5 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $67.3K. The largest seller was Scientech Research LLC, exiting entirely with an estimated $46K sold.
- 28 institutional investors held Aprea Therapeutics (APRE) as of Q2 2026, up from 22 in Q1 2026.
- Funds reported $1.9M of Aprea Therapeutics stock for Q2 2026, up 11% quarter-over-quarter.
- 8 funds opened new Aprea Therapeutics positions in Q2 2026 and 2 closed out, a net change of +6 holders.
- The largest Aprea Therapeutics buyer in Q2 2026 was Renaissance Technologies, an estimated $67.3K added.
- The largest Aprea Therapeutics seller in Q2 2026 was Scientech Research LLC, an estimated $46K sold.
Based on aggregated 13F filings for Q2 2026.